Laboratorio de Fisiología, Instituto de Investigaciones Médico-Biológicas, Universidad Veracruzana, Veracruz.
Departamento de Endoscopia, Hospital Ángeles del Pedregal, Ciudad de México.
Cir Cir. 2020;88(5):635-642. doi: 10.24875/CIRU.20001299.
Colorectal cancer (CRC) is one of the main five causes of morbidity and mortality by oncologic diseases in our country and worldwide. Recently, fecal immunochemical test (FIT) has proven to be a noninvasive screening test that allows to select patients most likely to have a pre-malign lesion in order to perform a colonoscopy.
To report the findings of a CRC screening program using FIT in our country population.
A multicentric study was performed, by inviting open population older than 50 years to participate in a CRC screening. Quantitative FIT specific for human hemoglobin was used, with a cut point of 100 ng/ml or higher to consider as positive. Those patients with positive results were asked to undergo a colonoscopy. In the cases where polypoid lesions were found, biopsies were performed.
In total, 751 FIT were processed, and 51 (6.8) of those were positive, with a rate of 15.9 premalign lesions for 1,000 individuals, and 1.3 patients with CRC for every 1,000.
The present study matches worldwide reports, supporting the initiative of establishing a formal and standardized CRC screening program in the public health sector.
结直肠癌(CRC)是我国乃至全球导致发病率和死亡率的主要五大肿瘤疾病之一。最近,粪便免疫化学检测(FIT)已被证明是一种非侵入性的筛查试验,可以选择最有可能存在癌前病变的患者,以便进行结肠镜检查。
报告我国人群使用 FIT 进行 CRC 筛查计划的结果。
进行了一项多中心研究,邀请 50 岁以上的开放性人群参加 CRC 筛查。使用针对人血红蛋白的定量 FIT,以 100ng/ml 或更高的截断值作为阳性判断标准。对阳性结果的患者要求进行结肠镜检查。在发现息肉样病变的情况下,进行活检。
共处理了 751 份 FIT,其中 51 份(6.8%)为阳性,每 1000 人中有 15.9 个癌前病变,每 1000 人中有 1.3 例 CRC。
本研究与全球报告一致,支持在公共卫生部门建立正式和标准化的 CRC 筛查计划的倡议。